迪瑞医疗收盘上涨2.04%，滚动市盈率117.84倍，总市值42.19亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Dirui Medical, indicating a significant decline in revenue and profit in the latest quarterly report [1][2] - As of August 8, Dirui Medical's stock closed at 15.47 yuan, with a PE ratio of 117.84, marking a new low in 91 days, and a total market capitalization of 4.219 billion yuan [1] - The average PE ratio for the medical device industry is 55.70, with a median of 39.08, positioning Dirui Medical at 107th place within the industry [1][2] Group 2 - Dirui Medical's main business involves the research, production, marketing, and service of medical testing instruments and related reagents, with key products including urine analysis, biochemical analysis, and blood cell analysis [1] - The company holds 213 patents, including 136 invention patents and 96 software copyrights [1] - In the first quarter of 2025, Dirui Medical reported a revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.6787 million yuan, down 87.13%, with a gross margin of 42.78% [1]